icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
eNq1mF1v2jAUhu/5FVHuSRpWBpsC1cbaDalVGS3atJvKJIdi5trpsc3Hfv0cQjc6Oepq8GVi5z0nPq8fHzk9Wz+wYAkoqeC9MIlOwgB4JnLK73vh5Pai2Q3P+o10QZZkb5qZF7VaYZAxImUvLEejKRAuo+9Xl5/AfA8Y9htBKqYLyNSzeVpRFn0hcn5FinJOkC4FzYMHUHOR98JCq+3bIJUKTRb9lcCfsiAZpPHuzf7o4u50/30al2L/oaol4CXh91ZR4E6amUYErgZEwb3ATU2+b5y0qRyDFBozGBE1H6FY0hxya4gZYRKcgsxW+Q3gkoEqg1jF40X2IJ3EyYKsx/A4tCf9wYwO1Fo1T5pJp9U6OW2/TdrdbsspFO4tlb0K5ifi7C7ptJOk04mBx7BhQBwrMxKoCPNUEyoHz23lKQ7C44u1z6ksGNlEC1m4LhVBYoYBzeb39yPlH9yiwREza/aPPteMxa/MerKDhaeMSxYNhOaqhhkXY9eFGAiuYF1fUTfMqfXOixTk8WR/CW5H/EhPGc1cgWaQo0GqyXhYz7PjoeAjkTBBfyz4RnkuVvL4jNmvqafsiy0mraIF5sld613XML/tvIV+GAPVnC7nGkUBsaEPlYdAZchn4lCcGE/apZ4ceSQzbjsckREGNT1O05ErxoVPLZk3n/vbQ9WAVfTz+a2rOb5qwM3N9tEqTfPen7K6QdcHyY0VaxN/vbGr/e2l+9Vo58ZcqUK+j+PVahXNiWxKYlYpmuGRqb53jPrrvL2c1VXvUpHRU+rT6sh7XX1c99lLp/mhHeru+10nbI2hUMMBtaiQ7A2cw/Pjs/hve+ot7dEzdvgLs20liaKC+2py9NSqeBj9TV35BRpAXM9mtOYmpNaXaVzdwvQbaVzewPQbvwGKmeEy
fng1MZQKxM8XjESx
Listen
